Neoadjuvant Treatment of HER2-positive Breast Cancer: Should Therapy Differ Based on Hormone Receptor Status?

Therapeutic Advances in Medical Oncology - United States
doi 10.1177/1758835918782356
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

SAGE Publications

Related search

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Current Neoadjuvant Treatment Options for HER2 Positive Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2011English

Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer

Journal of Breast Disease
2018English

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2016English

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

Efficacy of Neoadjuvant Therapy With Trastuzumab Concurrent With Anthracycline- And Nonanthracycline-Based Regimens for HER2-positive Breast Cancer

Cancer
Cancer ResearchOncology
2011English

Targeted Therapy for HER2 Positive Breast Cancer

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2018English

Overall Survival and Progression-Free Survival With Endocrine Therapy for Hormone Receptor-Positive, HER2-negative Advanced Breast Cancer: Review

Therapeutic Advances in Medical Oncology
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy